Zydus Lifesciences Ltd reports Phase 2b MASH trial results for saroglitazar, with 39.1% achieving disease resolution on 4 mg
- At week 52, resolution of steatohepatitis without worsening fibrosis was 39.1% with 4 mg and 32.4% with 2 mg, versus 13.7% on placebo.
- The 4 mg dose’s improvement in fibrosis by at least one stage was not statistically significant.
- Treatment was generally well tolerated, with no significant weight gain or drug-induced liver injury signal; saroglitazar remains investigational for MASH.
- Results are slated for presentation at AASLD 2026.
